Dreger Peter, Ahmed Sairah, Bazarbachi Ali, Dietrich Sascha, Fenske Timothy S, Ghosh Nilanjan, Hermine Olivier, Hamadani Mehdi
Department Medicine V, University of Heidelberg, Heidelberg, Germany.
Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02599-x.
Cellular therapies have been cornerstones of the treatment of mantle cell lymphoma (MCL) for decades and have helped to improve the outcome of this formerly very unfavourable B-cell lymphoma considerably. Current established roles of cellular therapies include autologous hematopoietic cell transplantation (HCT) as part of first-line therapy, chimeric antigen receptor-engineered T-cells (CART) for relapsed/refractory MCL, and allogeneic HCT for settings in which CARTs have failed or are unavailable. Therapeutic innovations have recently entered the MCL treatment landscape and are moving upstream in treatment algorithms, challenging the existing management principles. The purpose of this paper is to give some guidance regarding how to best use cellular therapies in this increasingly complex environment. Due to differences in CART labels, available non-cellular treatment options, and philosophy between the American and the European health systems, we found it reasonable to contrast the American and European perspectives on defined standard scenarios, which are often overlapping but show discrepancies in some important aspects.
几十年来，细胞疗法一直是套细胞淋巴瘤（MCL）治疗的基石，并极大地改善了这种原本预后极差的B细胞淋巴瘤的治疗结果。目前细胞疗法已确立的作用包括作为一线治疗一部分的自体造血细胞移植（HCT）、用于复发/难治性MCL的嵌合抗原受体工程T细胞（CART），以及用于CART治疗失败或无法使用的情况下的异基因HCT。治疗创新最近已进入MCL治疗领域，并在治疗算法中向上游发展，对现有的管理原则构成挑战。本文的目的是就如何在这个日益复杂的环境中最佳地使用细胞疗法提供一些指导。由于CART标签、可用的非细胞治疗选择以及美国和欧洲医疗系统之间理念的差异，我们发现对比美国和欧洲对特定标准情况的观点是合理的，这些情况通常相互重叠，但在一些重要方面存在差异。
